Inhalation of human insulin (Exubera) augments the efficiency of muscle glucose uptake in vivo

Diabetes

Volumn 55, Issue 12, 2006, Pages 3604-3610

  Edgerton, Dale S ^a,e   Cherrington, Alan D ^a   Williams, Phillip ^a   Neal, Doss W ^a   Scott, Melanie ^a   Bowen, Larry ^b   Wilson, Warren ^b   Hobbs, Charles H ^b   Leach, Chet ^b   Kuo, Mei Chang ^c   Strack, Thomas R ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c NEKTAR THERAPEUTICS   (United States)

^d PFIZER INC   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; ISOPHANE INSULIN; TRACER;

ALGORITHM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HINDLIMB; IN VIVO STUDY; INFERIOR CAVA VEIN; INSULIN BLOOD LEVEL; LIVER; LIVER SINUSOID; MUSCLE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; STEADY STATE;

ADMINISTRATION, INHALATION; ALGORITHMS; FASTING; FEMALE; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; KINETICS; LIVER; MUSCLE, SKELETAL; REFERENCE VALUES;

EID: 33845523536     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0718     Document Type: Article

References (32)

1. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U: Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27:162-167, 2004
2. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2622-2627, 2004
3. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC: Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 28:1630-1635, 2005
4. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Pena A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49:891-899, 2006
5. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2356-2362, 2004
6. Devries JH: Mealtime inhaled insulin lowers fasting glucose: a look at possible explanations. Diabetologia 48:2682-2683, 2005
7. Cherrington AD, Neal DW, Edgerton DS, Glass D, Bowen L, Hobbs CH, Leach C, Rosskamp R, Strack TR: Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes 53:877-881, 2004
8. Edgerton DS, Stettler KM, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Strack TR, Cherrington A: Inhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogs. J. Pharmacol Exp Ther. In press
9. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, Cherrington AD: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54:1164-1170, 2005
10. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann WC, Landau BR, Rossetti L, Cherrington AD: Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50:1872-1882, 2001
11. Moore MC, Hsieh PS, Neal DW, Cherrington AD: Nonhepatic response to portal glucose delivery in conscious dogs. Am J Physiol Endocrinol Metab 279:E1271-E1277, 2000
12. Galassetti P, Koyama Y, Coker RH, Lacy DB, Cherrington AD, Wasserman DH: Role of a negative arterial-portal venous glucose gradient in the postexercise state. Am J Physiol 277:E1038-E1045, 1999
13. Donmoyer CM, Chen SS, Hande SA, Lacy DB, Ejiofor J, McGuinness OP: Hyperinsulinemia compensates for infection-induced impairment in net hepatic glucose uptake during TPN. Am J Physiol Endocrinol Metab 279:E235-E243, 2000
14. Mari A: Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 263:E400-E415, 1992
15. Dobbins RL, Davis SN, Neal DW, Cobelli C, Cherrington AD: Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am J Physiol 266:E467-E478, 1994
16. Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22:2253-2261, 2004
17. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H: Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 38:1355-1360, 2001
18. Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH: Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 137:276-284, 2002
19. Tom B, Dendorfer A, Danser AH: Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 35:792-801, 2003
20. Henriksen EJ, Jacob S: Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 5:214-222, 2003
21. Henriksen EJ, Jacob S: Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196:171-179, 2003
22. Damas J, Garbacki N, Lefebvre PJ: The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabete Metab Res Rev 20:288-297, 2004
23. Couture R, Girolami JP: Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500:467-485, 2004
24. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME: Why blockade of the renin-angiotensin system reduces the incidence of newonset diabetes. J Hypertens 23:463-473, 2005
25. Krulewitz AH, Baur WE, Fanburg BL: Hormonal influence on endothelial cell angiotensin-converting enzyme activity. Am J Physiol 247:C163-C168, 1984
26. Erman A, Chen-Gal B, David I, Giler S, Boner G, van Dijk DJ: Insulin treatment reduces the increased serum and lung angiotensin converting enzyme activity in streptozotocin-induced diabetic rats. Scand J Clin Lab Invest 58:81-87, 1998
27. Valentovic MA, Elliott CW, Ball JG: The effect of streptozotocin-induced diabetes and insulin treatment on angiotensin converting enzyme activity. Res Commun Chem Pathol Pharmacol 58:27-39, 1987
28. Erman A, van Dyk DJ, Chen-Gal B, Giler ID, Rosenfeld JB, Boner G: Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur J Clin Invest 23:615-620, 1993
29. UKPDS Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720, 1998
30. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
31. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M: Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890, 2001
32. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ: ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 277:R332-R336, 1999